{"name":"Rare Disease Venture Atlas Agent","description":"Open translational & venture diligence specialist agent covering all 7,000+ orphan diseases live (OpenTargets + ClinicalTrials.gov v2 + PubMed + FDA Orphan unit economics) plus 6 curated hematology/immunology deep-dives anchored on Paired Myelofibrosis Flagships: Clonal JAK2 V617F+ Primary Myelofibrosis ('jak2-myelofibrosis', JH2 vs JH1 selectivity, INCB160058 NCT06313593, AJ1-11095 NCT06343805, INCA033989 NCT06034002) and Reversible JAK2-Negative Autoimmune Myelofibrosis ('autoimmune-myelofibrosis', AIMF 74-80% human marrow fibrosis reversal + IL-6/STAT3/hepcidin/ferroportin iron overload), alongside VEXAS Syndrome (UBA1), Castleman Disease (iMCD), Systemic Mastocytosis (KIT D816V), and Telomere Biology Disorders (TERT/TERC/PAPD5).","url":"https://api.rare-disease-atlas.workers.dev/a2a","documentationUrl":"https://rare-disease-atlas.github.io/llms-full.txt","provider":{"organization":"Rare Disease Venture Atlas","url":"https://rare-disease-atlas.github.io"},"version":"1.6.0","protocolVersion":"0.3.0","preferredTransport":"JSONRPC","capabilities":{"streaming":false,"pushNotifications":false,"stateTransitionHistory":false},"defaultInputModes":["text/plain","application/json"],"defaultOutputModes":["text/plain","application/json"],"skills":[{"id":"search-orphan-venture-wedges","name":"Search Orphan Disease Startup Blueprints (Myelofibrosis-Anchored)","description":"Searches startup blueprints anchored on Clonal JAK2 V617F+ Myelofibrosis and Reversible Autoimmune Myelofibrosis (plus VEXAS, Castleman, Mastocytosis, and Telomere cohorts) by founder track, capital tier, and wet-lab requirement.","tags":["myelofibrosis","rare-disease","venture","biotech","ai-bio","public-health"],"examples":["Search zero-wet-lab computational AI/ML startup wedges under $250K seed budget.","What public-health diagnostic wedges exist for misdiagnosed myelofibrosis?"]},{"id":"jak2-clonal-myelofibrosis-diligence","name":"Clonal JAK2 V617F+ Myelofibrosis Translational Diligence","description":"Synthesizes JH2 pseudokinase allosteric selectivity (PDB 4FVQ/4FVR) vs pan-JAK1/2 JH1 ATP-site inhibition failure modes, active clinical trials (INCB160058 NCT06313593, AJ1-11095 NCT06343805, INCA033989 NCT06034002, pelabresib NCT04603495, imetelstat NCT04576156), and single-cell marrow datasets (GSE144568, GSE156644).","tags":["myelofibrosis","JAK2-V617F","JH2","CALR","clinical-trials"],"examples":["Explain JH2 vs JH1 selectivity in JAK2 V617F myelofibrosis and active NCT trials."]},{"id":"autoimmune-myelofibrosis-iron-triage","name":"Autoimmune Myelofibrosis (AIMF) & Iron Overload Positive-Control Triage","description":"Contrasts clonal PMF against reversible JAK2-negative lupus/autoimmune myelofibrosis (74-80% marrow fibrosis reversal MF-2/3 -> MF-0/1 within 8-16 weeks on glucocorticoids/rituximab/mycophenolate) and dual transfusional + IL-6 -> STAT3 -> hepcidin (HAMP) -> ferroportin (SLC40A1) iron overload.","tags":["autoimmune-myelofibrosis","AIMF","lupus","SLE","hepcidin","iron-overload","fibrosis-reversal"],"examples":["How does JAK2-negative autoimmune myelofibrosis with lupus suspicion and iron overload differ from triple-negative PMF?"]},{"id":"non-dilutive-grant-stacking","name":"Orphan Disease Non-Dilutive Capital & 90-Day Diligence Roadmaps","description":"Maps NIH/NCI SBIR/STTR, ARPA-H, MPN Research Foundation, LLS Therapy Acceleration Program (TAP), CDCN, and FDA Orphan Drug incentives alongside 30/60/90-day validation plans.","tags":["grants","SBIR","ARPA-H","non-dilutive","orphan-drug"],"examples":["Retrieve a 90-day diligence plan and non-dilutive grant stack for a myelofibrosis AI drug repurposing team."]},{"id":"stress-test-orphan-hypothesis","name":"Stateless Translational & Venture Hypothesis Red-Team Oracle","description":"Executes an 8-rule translational & venture stress-test combining live OpenTargets v4, ClinicalTrials.gov v2, and PubMed lookups with Myelofibrosis & Orphan failure-mode checks (spleen-only SVR35 endpoint traps, reversible ANA+ Autoimmune Myelofibrosis AIMF mimicry, conserved JH1 WT JAK2 toxicity vs JH2 V617F allosteric selectivity, hepcidin mimetic vs suppressor polarity, trial crowding, zero-wet-lab CRO feasibility, and FY2026 FDA Orphan unit economics).","tags":["stress-test","red-team","myelofibrosis","JH2","AIMF","hepcidin","clinical-trials","orphan-drug"],"examples":["Stress-test a spleen-only SVR35 pan-JAK inhibitor in triple-negative myelofibrosis.","Red-team an ACVR1/hepcidin-lowering combination vs rusfertide in anemic myelofibrosis."]}],"x402":{"paymentRequired":false,"priceUsd":"0"},"erc8004":{"status":"ready","trustModel":"open-science-public-good"}}